drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentiviral CAR T cells specific for CLL-1 (CLEC12A); IV infusion with dose escalation; intended to eliminate CLL-1+ myeloid leukemia stem cells and myeloid blasts via MHC-independent mechanisms.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered T cells (via lentiviral transduction) expressing a CAR that recognizes CLL‑1/CLEC12A on myeloid leukemia stem cells and blasts. Antigen binding activates T cells independent of MHC, inducing cytotoxicity (perforin/granzyme) and cytokine release to eliminate CLL‑1–positive malignant cells.
drug_name
CLL-1 (CLEC12A)-directed CAR T cells
nct_id_drug_ref
NCT06849921